Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12540716 | 1.00 | ESR2 (0.56) | ESR2BRD4MAP1LC3BKDM1AKCNH2 | |
| SCHEMBL12540718 | 1.00 | ESR2 (0.56) | ESR2BRD4MAP1LC3BKDM1AKCNH2 | |
| SCHEMBL15541691 | 0.81 | ESR2 (0.55) | ESR2MAP1LC3BKDM4E | |
| SCHEMBL15541693 | 0.81 | ESR2 (0.55) | ESR2MAP1LC3BKDM4E | |
| SCHEMBL3322034 | 0.81 | ESR2 (0.55) | ESR2MAP1LC3BKDM4E | |
| SCHEMBL3322032 | 0.81 | ESR2 (0.55) | ESR2MAP1LC3BKDM4E | |
| SCHEMBL6337866 | 0.76 | KDM4E (0.43) | KDM4E | |
| SCHEMBL14620989 | 0.72 | ESR2 (0.55) | ESR2CYP19A1 | |
| SCHEMBL18246497 | 0.72 | ESR2 (1.00) | ESR2 | |
| SCHEMBL2046094 | 0.72 | ESR2 (0.50) | ESR2BRD4MAP1LC3BKDM1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103635458-B | Trpv1 antagonists | 艾伯维公司 | 2016-10-19 | — | — | CN | disclosed |
| US-8802711-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2014-08-12 | — | — | US | disclosed |
| CN-103635458-A | Trpv1 antagonists | ABBVIE INC | 2014-03-12 | — | — | CN | disclosed |
| EP-2688866-A1 | TRPV1 ANTAGONISTS | AbbVie Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012134943-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120245163-A1 | TRPV1 Antagonists | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245163-A1 | TRPV1 Antagonists | TRPV1, TRPV3, TRPV6 | ESR2 1315/4885BRD4 907/4885MAP1LC3B 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.